Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1998 1
1999 1
2002 3
2003 1
2004 5
2005 2
2006 1
2007 2
2009 1
2010 1
2011 4
2012 2
2013 1
2014 3
2017 2
2018 4
2019 1
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H. Joensuu H, et al. Among authors: villman k. J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12. J Clin Oncol. 2022. PMID: 35020465 Free PMC article. Clinical Trial.
Reply to a. Levy et Al.
Wickberg A, Holmberg L, Adami HO, Magnuson A, Villman K, Liljegren G. Wickberg A, et al. Among authors: villman k. J Clin Oncol. 2014 Oct 10;32(29):3340. doi: 10.1200/JCO.2014.56.8493. Epub 2014 Aug 25. J Clin Oncol. 2014. PMID: 25154817 No abstract available.
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).
Lindman H, Andersson M, Ahlgren J, Balslev E, Sverrisdottir A, Holmberg SB, Bengtsson NO, Jacobsen EH, Jensen AB, Hansen J, Tuxen MK, Malmberg L, Villman K, Anderson H, Ejlertsen B, Bergh J, Blomqvist C; Swedish Breast Cancer Group (SweBCG), the Danish Breast Cancer Group (DBCG) and the Scandinavian Breast Cancer Group (SBG). Lindman H, et al. Among authors: villman k. Eur J Cancer. 2018 May;94:79-86. doi: 10.1016/j.ejca.2018.02.016. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29547834 Clinical Trial.
NQO1 expression correlates inversely with NFκB activation in human breast cancer.
Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, Mattson J, Villman K, Vrtel R, Lukas J, Heikkilä P, Blomqvist C, Bartek J, Nevanlinna H. Jamshidi M, et al. Among authors: villman k. Breast Cancer Res Treat. 2012 Apr;132(3):955-68. doi: 10.1007/s10549-011-1629-5. Epub 2011 Jun 25. Breast Cancer Res Treat. 2012. PMID: 21706157
Expression of Ephb2 and Ephb4 in breast carcinoma.
Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Wu Q, et al. Among authors: villman k. Pathol Oncol Res. 2004;10(1):26-33. doi: 10.1007/BF02893405. Epub 2004 Mar 18. Pathol Oncol Res. 2004. PMID: 15029258 Free article.
35 results